NCCN 2019 Annual Congress: Hematologic Malignancies™

Congress Overview

World-renowned experts in the management of Hematologic Malignancies present the latest treatment advances, updates to the standard of care as recommended in the NCCN Guidelines®, and unique and challenging patient cases.

Co-chaired by Ranjana H. Advani, MD, Stanford Cancer Institute and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, this one-and-a-half day program features presentations and panel discussions on patient cases highlighting the treatment options and supportive care for a variety of hematological malignancies.

Intended Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies. 

Educational Objectives

Goal of Education and Overall Congress Objectives:

The ultimate goal for NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians. The goal of the NCCN 2019 Annual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:

  • Apply the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with various hematologic malignancies.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.


Session Learning Objectives:

After completing this program, participants should be able to:

Debate – Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?
  • Summarize the evidence from recent clinical trials supporting the use of targeted therapy for patients with newly diagnosed chronic lymphocytic leukemia.
  • Recognize the emerging role of IGHV mutation status in the selection of first-line therapy, and identify patients with newly diagnosed chronic lymphocytic leukemia who could be candidates for chemoimmunotherapy.
  • Develop an individualized treatment plan for patients with newly diagnosed chronic lymphocytic leukemia based on the disease-specific and patient-specific characteristics.

Updates in Treatment Strategies for Hodgkin Lymphoma
  • Summarize current standard treatment options for patients with classic Hodgkin lymphoma.
  • Identify novel therapeutic agents or regimens and how to incorporate them into the management of patients with advanced or relapsed or refractory Hodgkin lymphoma.
  • Outline potential strategies to consider when developing treatment plans for patients with Hodgkin lymphoma, including prognostic markers and sequence of treatment.

Patient Case Studies and Panel Discussion: Lymphoma
  • Identify clinical challenges in managing patients with lymphoma.
  • Develop an evidence-based approach for the management of these patients.

Patient Case Studies and Panel Discussion: Leukemia – Rare and Emerging Subtypes
  • Identify clinical challenges in managing patients with leukemia.
  • Develop an evidence-based approach for the management of these patients.

Management of Recurrent Acute Lymphoblastic Leukemia with T-Cell Engagement: CAR T, BiTEs, and Beyond
  • Summarize key studies that have utilized immunotherapies in relapsed or refractory acute lymphoblastic leukemia.
  • Develop appropriate management strategies for adverse events associated with immunotherapies in relapsed or refractory acute lymphoblastic leukemia.
  • Discuss strategies that may improve the efficacy of immunotherapies in relapsed or refractory acute lymphoblastic leukemia.

Therapeutic Advances in First-Line Acute Myeloid Leukemia Management
  • Summarize novel treatment options and incorporate these into the management of acute myeloid leukemia to optimize patient outcomes.
  • Outline molecular markers or genes with prognostic significance in acute myeloid leukemia and associated targeted agents.
  • Identify emerging targeted agents and incorporate these into the management of appropriate subpopulations of patients with acute myeloid leukemia.

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes
  • Summarize current standard treatment options for patients with myelodysplastic syndromes.
  • Identify gene mutations that impact treatment of myelodysplastic syndromes.
  • Describe emerging personalized treatment strategies for the management of myelodysplastic syndromes.

Debate – Fixed Duration Versus Until Progression: How Long Should the Initial Treatment of Myeloma Last?
  • Assess available evidence supporting various durations of first-line therapy for patients with multiple myeloma—fixed duration versus continuous until disease progression.
  • Compare and contrast the benefits and limitations of fixed duration versus therapy until progression for initial treatment of multiple myeloma.
  • Select appropriate evidence-based strategies for management of patients with newly diagnosed multiple myeloma taking into consideration individual patient characteristics, such as age, cytogenetic risk, frailty, comorbidities, and other risk factors.

Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
  • Identify clinical challenges in managing patients with plasma cell neoplasms.
  • Develop an evidence-based approach for the management of these patients.

Evolution of Therapy for Relapsed/Refractory Multiple Myeloma
  • Evaluate clinical data supporting the current treatment options for patients with relapsed/refractory multiple myeloma.
  • Recommend appropriate therapies for relapsed/refractory multiple myeloma taking into consideration patient and clinical factors.
  • Review emerging treatment options and counsel patients regarding ongoing clinical trials.

The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know
  • Describe the regulatory process for the evaluation and approval of biosimilar mAbs and the rationale for extrapolation across other indications.
  • Identify the biosimilar mAbs that are FDA-approved and the indications for their clinical use.
  • Review the efficacy and safety data from the comparative clinical trials that have evaluated biosimilar mAbs and their reference biological products to inform decision making.

Diagnosis and Management of Castleman’s Disease
  • Identify the clinical and pathological features associated with the different subtypes of Castleman’s disease.
  • Review the recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) B-Cell Lymphomas for management of patients with unicentric Castleman’s disease.
  • Develop an individualized treatment plan for patients with multicentric Castleman’s disease based on the organ involvement and HIV or HHV8 infection status.

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemo-Free Therapy?
  • Describe the standard first-line therapy and the rationale for the development of novel treatment options for follicular lymphoma.
  • Review the evidence from clinical trials supporting the use of a chemotherapy-free approach for the management of newly diagnosed follicular lymphoma.
  • Develop an individualized treatment plan for follicular lymphoma incorporating a chemotherapy-free approach based on the patient and disease-specific factors.

Accreditation

Accreditation Statements

Joint Accreditation Logo 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses 

NCCN designates this educational activity for a maximum of 8.5 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 8.5 contact hours (0.85 CEUs) of continuing education credit. UAN: JA4008196-0000-19-064-L01-P

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Catergory 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for 8.5 AAPA Catergory 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

CME-MOC graphic 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification (MOC)

ABPLogo 

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Maintenance of Certification program. Participants may earn up to 8.5 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.
 
American Board of Medical Specialties Maintenance of Certification (MOC)

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, the NCCN 2019 Annual Congress: Hematologic Malignancies has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Pathology
Radiology
 

Requirements for Receiving CE Credit

Before or during the activity, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Log in at https://www.nccn.org 

  • If you do not have an NCCN account, click "Sign up here" to create one for free

 

2. Click “Profile” in the left side menu

3. Verify that your User Type matches the type of credit you will claim:

  • Physician/Surgeon/Oncologist = AMA PRA Category 1 Credits™; ABIM/ABPath MOC points, if applicable*
  • Physician Assistant = AAPA Category 1 CME credits
  • Nurse Practitioner = ANCC contact hours
  • Pharmacist = ACPE contact hours**
  • Clinical Nurse Specialist = ANCC contact hours
  • Nurse/Oncology Nurse = ANCC contact hours
  • Case Manager (Nurse) = ANCC contact hours
  • All other user types = certificate of participation

 

4. Scroll down and click "Save" if you make any changes

Immediately following the educational activity, you will receive an e-mail with instructions on how to complete the CE requirements online through NCCN’s Continuing Education Portal (http://education.nccn.org/hem). Within 30 days of the activity, you must:

  • Attend the activity
  • Complete the immediate post-test
  • Complete the evaluation
  • Claim your credits

 

You will be able to view/print your certificate online once all requirements have been met.

*Physicians claiming ABIM or ABPath MOC points: ABIM/ABPath MOC points are reported to ABIM/ABP once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your ABIM/ABP learner ID and date of birth. Your credit cannot be reported without this information.

**Pharmacists: You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Your credit cannot be reported without this information.

If you have any questions, please e-mail education@nccn.org.


NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
 

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top